Advisors Preferred’s Alexion Pharmaceuticals ALXN Stock Holding History

Advisors Preferred’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-4,045	Closed	-$463K	–	214
2020 Q3	$463K	Sell	4,045 -1,552	-28%	-$167K	0.09%	51
2020 Q2	$629K	Buy	+5,597	New	+$594K	0.18%	42
2020 Q1	–	Sell	-1,233	Closed	-$133K	–	288
2019 Q4	$133K	Buy	+1,233	New	+$132K	0.04%	128
2017 Q4	–	Sell	-2,225	Closed	-$312K	–	278
2017 Q3	$312K	Buy	+2,225	New	+$302K	0.18%	66
2015 Q4	–	Sell	-17	Closed	-$3K	–	277
2015 Q3	$3K	Buy	+17	New	+$3.1K	﹤0.01%	180

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Advisors Preferred's ALXN Position: Q4 2020 in Review

Advisors Preferred sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 4,045 shares — an estimated $463K sold.

Advisors Preferred first reported a position in ALXN in Q3 2015 and held it in 5 quarters. The position peaked at $629K in Q2 2020. 827 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

Advisors Preferred reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Advisors Preferred sold 4,045 Alexion Pharmaceuticals shares in Q4 2020, an estimated $463K.
Advisors Preferred first reported a position in Alexion Pharmaceuticals in Q3 2015 and held it in 5 quarters.
Advisors Preferred's Alexion Pharmaceuticals position peaked at $629K in Q2 2020.
827 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on Advisors Preferred's 13F filing for Q4 2020, filed 3 Feb 2021.